engineered EVs loaded with the STING agonist cyclic GMP-AMP suppressed B16F10 tumor growth and increased accumulation of activated CD8+ T-cells and enhanced anti-tumor immunity (McAndrews et al., 2021). The gene discussed is CD8A; the disease is neoplasm.